OSR Holdings, Inc. has filed an amendment to its previous 8-K report, originally submitted on April 2, 2026. The amendment, designated as 8-K/A, serves to correct clerical errors found in Exhibit 10.1, which pertains to the Global License Agreement for VXM01 dated March 23, 2026. The errors included inaccuracies in the stated per share price. Importantly, this amendment does not introduce any new information or changes to the substantive content of the original report. The company emphasizes that no other disclosures have been modified, amended, or updated in this filing. The corrected agreement involves OSR Holdings, Vaximm AG, and BCM Europe AG, and is crucial for the ongoing development of the VXM01 oral cancer immunotherapy platform. The filing is part of OSR Holdings' commitment to transparency and compliance with SEC regulations, ensuring that all stakeholders have access to accurate and up-to-date information regarding the company's agreements and operational activities.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.